KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.95

Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.

Ravin Ratan, Bernd Kasper, Thierry Alcindor, Patrick Schöffski, Winette T A van der Graaf, Noah Federman, Nam Q Bui, Gina D'Amato, Richard F Riedel, Steven Attia, Sant Chawla, Allison Lim, Brad Tumminello, Ana B Oton, Yucheng Chu, Shengfan Zhou, Mrinal Gounder

J Clin Oncol 43(34) 3646-3651

PMID41115259
PMCIDPMC12634144
DOI10.1200/JCO-25-00582
发表日期2025-10-20
入排依据:Meets all criteria: Phase III randomized drug trial in human oncology (desmoid tumors) with a primary time-to-event (PFS) endpoint and original result reporting.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIG 1.:AI 判定为 flow diagram;FIG 2.:AI 判定为 other;FIG 3.:非 KM 图。
摘要

摘要

In the phase III placebo-controlled DeFi trial (ClinicalTrials.gov identifier: NCT03785964) primary analysis, nirogacestat showed significant improvement versus placebo in progression-free survival (PFS), objective response rate (ORR), and patient-reported outcomes (PRO) in adult patients with progressing desmoid tumors (DT; median [range] exposure: 20.6 [0.3-33.6] months). Here, long-term nirogacestat efficacy and safety were evaluated in patients randomly assigned to nirogacestat and followed through the final data cutoff date of December 19, 2024. End points included PFS and ORR per RECIST v1.1, PRO, and safety. The median (range) duration of exposure was 33.6 (0.3-61.8) months. Median PFS was not reached. The ORR with up to 4 years of nirogacestat treatment was 45.7% (32 of 70), with three additional partial and three additional complete responses since the primary analysis. Further target tumor size reduction occurred in most patients. Benefits in PROs were sustained while on treatment. Frequently reported treatment-emergent adverse events (TEAEs) decreased in incidence and severity over time. Since the primary analysis, four patients discontinued nirogacestat because of TEAEs between years 2 and 4. In conclusion, long-term continuous nirogacestat treatment was associated with further tumor size reductions, durable objective responses, sustained PRO benefits, and a manageable safety profile consistent with the primary analysis.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.DeFi trial design. a After imaging-based disease progression or primary analysis completion, patients were unblinded and given the option to enroll in an open-label extension phase if eligible.
非 KM Figure
FIG 2.Percent change from baseline in sum of largest diameter (mm) of target tumor size per RECIST v1.1 by best overall response (n = 66 a ). Best overall response was defined as the best response obtained across all assessments per independent central review. Partial response and complete response required confirmation by subsequent scans. a One patient had no tumor size assessments, and three patients had missing postbaseline tumor size measurements. RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1.
非 KM Figure
FIG 3.Frequency of new-onset TEAEs (≥15%) reported with nirogacestat per timeframe by greatest severity and listed in order of frequency (safety population). Percentages were based on the number of patients in the safety population who reached the presented timeframe. TEAEs were coded using MedDRA v24.0. TEAEs were defined as any AE with initial onset or increasing in severity after the initiation of nirogacestat treatment through 30 days after the last dose of nirogacestat on study or the last dose date if starting with another treatment for DT (eg, patient goes onto the Continued Access Plan or continues with the commercial nirogacestat). If a patient experienced a coded event more than once, a single occurrence was presented at the greatest severity per timeframe. Patients with multiple occurrences for a given SOC/PT were only counted once for that SOC/PT at the timeframe of onset. TEAE severity was graded using CTCAE v5.0. OT was identified by investigators (both verbatim term and grade) in females of reproductive potential based on abnormal reproductive hormone values or perimenopausal symptoms or both. The verbatim terms for OT events were coded to the MedDRA preferred terms of ovarian failure, premature menopause, amenorrhea, menopause, oligomenorrhea, and ovarian disorder. AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; DT, desmoid tumors; MedDRA, Medical Dictionary for Regulatory Activities; OT, ovarian toxicity; SOC/PT, system organ class/preferred term; TEAE, treatment-emergent adverse event.
非 KM Figure